MRI scans and oral pimonidazole to study biomarkers in head and neck cancer
Tests MRI scans and oral pimonidazole in adults newly diagnosed with head and neck cancer.
Plain-language title generated from the registry record
Registry title: A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Princess Margaret Cancer CenterToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06085781
- Record updated
- 6 August 2026
- Original description
The purpose of this study is to explore biomarker development in patients with newly diagnosed Head and neck squamous cell carcinoma (HNSCC) receiving curative therapy.Read full original descriptionShow less
HN-BIO: A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers
The purpose of this study is to explore biomarker development in patients with newly diagnosed Head and neck squamous cell carcinoma (HNSCC) receiving curative therapy.
Inclusion: Age >/= 18 years; Histologically proven Head and Neck Squamous Cell carcinoma; Primary or nodal disease > 3cm for biomarker imaging; Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Planned for curative surgery or (chemo)radiotherapy; Willingness to undergo repeat MRI imaging; Able to receive and understand verbal and written information regarding study and able to give written informed consent; Adequate renal function: Calculated creatinine clearance >/= 30ml/min; Be able to lie comfortably on back for 1 hour.
Exclusion: Previous solid tumor treated within last 5 years; As judged by investigator evidence of systemic disease that makes unsuitable for study; History of gadolinium contrast allergy; Contra-indication for serial MRI scans; Pregnancy; Non-reversible clotting abnormality.